Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Dec

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Lung Cancer Screening May Increase Long-Term Survival Rate

High Deductibles May Discourage Patients From Receiving Additional Testing After an Abnormal Mammogram

Study Finds Americans Have a Low Awareness of the Link Between Alcohol Use and Increased Cancer Risk

Does CBD Oil Improve Symptom Distress in Patients With Advanced Cancer Receiving Palliative Care

Incidence of Cervical Cancer in Women in the United States 2001 to 2019